Cardiff Oncology (CRDF) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to -$0.17.
- Cardiff Oncology's EPS (Weighted Average and Diluted) rose 3200.0% to -$0.17 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.79, marking a year-over-year increase of 1595.74%. This contributed to the annual value of -$0.95 for FY2024, which is 257.36% down from last year.
- Latest data reveals that Cardiff Oncology reported EPS (Weighted Average and Diluted) of -$0.17 as of Q3 2025, which was up 3200.0% from -$0.21 recorded in Q2 2025.
- In the past 5 years, Cardiff Oncology's EPS (Weighted Average and Diluted) ranged from a high of -$0.14 in Q1 2021 and a low of -$0.26 during Q2 2024
- For the 5-year period, Cardiff Oncology's EPS (Weighted Average and Diluted) averaged around -$0.22, with its median value being -$0.22 (2023).
- Data for Cardiff Oncology's EPS (Weighted Average and Diluted) shows a peak YoY increase of 6666.67% (in 2021) and a maximum YoY decrease of 20000.0% (in 2021) over the last 5 years.
- Quarter analysis of 5 years shows Cardiff Oncology's EPS (Weighted Average and Diluted) stood at -$0.24 in 2021, then increased by 16.67% to -$0.2 in 2022, then fell by 5.0% to -$0.21 in 2023, then dropped by 17.85% to -$0.25 in 2024, then skyrocketed by 31.31% to -$0.17 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.17 in Q3 2025, compared to -$0.21 in Q2 2025 and -$0.2 in Q1 2025.